Jesús San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the value of sustained minimal residual disease (MRD) negativity in the context of the FORTE trial (NCT02203643) for patients with newly diagnosed multiple myeloma. The FORTE trial evaluated the safety and efficacy of carfilzomib combined with cyclophosphamide and dexamethasone (CCyd), or lenalidomide and dexamethasone (KRd) followed by autologous stem cell transplantation (ASCT) or 12 cycles of carfilzomib combined with dexamethasone and lenalidomide. The trial found the rate of MRD negativity to be similar with KRd consolidation with or without transplantation, however the progression-free survival (PFS) was longer in the KRd plus transplant arm. Dr Miguel highlights that this is due to sustained MRD negativity, which demonstrates the value of maintenance therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.